PMV Pharmaceuticals, Inc. (PMVP)
1.37
+0.03
(+2.24%)
USD |
NASDAQ |
Sep 09, 16:00
1.37
0.00 (0.00%)
After-Hours: 16:07
PMV Pharmaceuticals Enterprise Value : -7.577M for Sept. 8, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 08, 2026 | -7.577M |
| September 04, 2026 | -10.25M |
| September 03, 2026 | -12.92M |
| September 02, 2026 | -11.85M |
| September 01, 2026 | -10.25M |
| August 31, 2026 | -14.53M |
| August 28, 2026 | -13.99M |
| August 27, 2026 | -12.92M |
| August 26, 2026 | -9.181M |
| August 25, 2026 | -9.448M |
| August 24, 2026 | -9.448M |
| August 21, 2026 | -8.112M |
| August 20, 2026 | -9.716M |
| August 19, 2026 | -10.78M |
| August 18, 2026 | -12.92M |
| August 17, 2026 | -12.39M |
| August 14, 2026 | -11.85M |
| August 13, 2026 | -14.26M |
| August 12, 2026 | -11.85M |
| August 11, 2026 | -9.716M |
| August 10, 2026 | -13.46M |
| August 07, 2026 | -15.60M |
| August 06, 2026 | -16.13M |
| August 05, 2026 | -16.67M |
| August 04, 2026 | -16.67M |
| Date | Value |
|---|---|
| August 03, 2026 | -19.34M |
| July 31, 2026 | -19.87M |
| July 30, 2026 | -18.80M |
| July 29, 2026 | -22.01M |
| July 28, 2026 | -20.41M |
| July 27, 2026 | -16.13M |
| July 24, 2026 | -12.92M |
| July 23, 2026 | -8.112M |
| July 22, 2026 | -8.112M |
| July 21, 2026 | -9.181M |
| July 20, 2026 | -10.78M |
| July 17, 2026 | -7.577M |
| July 16, 2026 | -9.716M |
| July 15, 2026 | -4.369M |
| July 14, 2026 | -3.300M |
| July 13, 2026 | -10.78M |
| July 10, 2026 | -12.92M |
| July 09, 2026 | -12.92M |
| July 08, 2026 | -12.39M |
| July 07, 2026 | -12.92M |
| July 06, 2026 | -14.79M |
| July 02, 2026 | -13.99M |
| July 01, 2026 | -12.92M |
| June 30, 2026 | -7.577M |
| June 29, 2026 | -24.46M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.865B |
| Alnylam Pharmaceuticals, Inc. | 34.46B |
| Anika Therapeutics, Inc. | 268.42M |
| Savara, Inc. | 993.23M |
| Vericel Corp. | 1.932B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.09M |
| Total Expenses (Quarterly) | 18.09M |
| EPS Diluted (Quarterly) | -0.3388 |
| Earnings Yield | -103.1% |
| Normalized Earnings Yield | -103.13 |